Mersana Therapeutics Inc (NAS:MRSN)
$ 2.37 0.07 (3.04%) Market Cap: 292.77 Mil Enterprise Value: 160.46 Mil PE Ratio: 0 PB Ratio: 237.00 GF Score: 29/100

Mersana Therapeutics Inc UpRi Clinical Data Update Call Transcript

Sep 10, 2021 / 12:00PM GMT
Release Date Price: $8.56 (-39.12%)
Operator

Good morning, and welcome to Mersana Therapeutics Conference Call and webcast. (Operator Instructions) I would now like to turn the call over to Sarah Carmody, Executive Director, Investor Relations and Corporate Communications. Please proceed.

Sarah Carmody
Mersana Therapeutics, Inc. - Executive Director of IR & Corporate Communications

Good morning. Welcome to Mersana's Conference Call and webcast to report updated interim data from the UpRi ovarian cancer expansion cohort and provide a clinical development strategy update. A replay of today's call will be available on the Investors and media section of our website.

After our prepared remarks, we will open the call for Q&A. Before we begin, please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the federal securities laws. These may include statements about our clinical strategy for our product candidates, progression, design and timing of our clinical studies, including the company's next trial and data from our ongoing clinical

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot